{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', '9.7.', 'Symptomatic Overdose', 'In the event of an overdose of trial medication, the Investigator should use clinical judgment in', 'treating the signs and symptoms of the overdose. The signs and symptoms should be reported as', 'AEs/ADEs. Overdoses must be reported immediately to the trial Medical Monitor (or designee).', '9.8.', 'Serious Adverse Events (SAEs)/Serious Adverse Device Effect', '(SADEs)', 'A SAE/SADE is any AE/ADE that:', 'Results in death.', 'Is life-threatening. The term \"life-threatening\" refers to a situation in which the', 'subject is at risk of death at the time of the event; it does not refer to an event that', 'hypothetically might cause death if it were more severe.', 'Requires in-patient hospitalization or prolongation of existing hospitalization.', 'Results in persistent or significant disability/incapacity.', 'Is a congenital anomaly/birth defect.', 'Is a medically important event or reaction.', 'An SADE is an ADE that might have led to the SADE, in a participant, user or other person if a)', 'suitable action had not been taken or b) intervention had not been made or c) if circumstances', 'had been less fortunate. They are handled under the SAE reporting system.', 'Medical and scientific judgement should be exercised in deciding whether expedited reporting is', 'appropriate in other situations, such as important medical events that may not be immediately', 'life-threatening or result in death or hospitalization but may jeopardize the subject or may require', 'intervention to prevent one of the other outcomes listed in the definition above. These should', 'also usually be considered serious. Examples of such events are intensive treatment in an', 'emergency room or at home for allergic bronchospasm; blood dyscrasias, or convulsions that do', 'not result in hospitalization; or development of drug dependency or drug abuse.', 'Any non-serious AE/ADE that worsens and meets the criteria for a SAE/SADE should be', 'reported as a SAE/SADE. The start date of the SAE/SADE should be the date the AE/ADE', 'worsened to meet the criteria for a SAE/SADE.', 'The Investigator is expected to take all therapeutic measures necessary for resolution of the', 'SAE/SADE. Any medications or procedures necessary for treatment of the SAE/SADE must be', \"recorded on the subject's eCRF.\", 'As part of the routine medical monitoring, the medical monitor (or designee) will review all', 'SAEs/SADEs reported in the SPIMM-301 trial, looking for any safety data trends or trial IMP-', 'related issues.', '9.9.', 'Recording of Adverse Events (AEs)/Adverse Device Effects (ADEs)', 'Complete and accurate data on all AEs/ADEs experienced for the duration of the reporting', \"period (defined below) will be recorded on an ongoing basis on the subject's eCRF. All\", 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '65']['SPIMM-301 Version 4.0', '15 June 2018', 'SAEs/SADEs must be reported using the trial specific SAE Report Form, in addition to the', \"subject's eCRF.\", 'It is important that each AE/ADE entry include a verbatim term along with, onset and resolution', 'dates, severity, seriousness, relationship to the IMP, action taken with respect to the IMP, and its', 'outcome.', 'Investigators should use the AE/ADE definitions provided in the above sections and should', \"observe the following guidelines when completing the subject's eCRF:\", 'Whenever possible, recognized medical terms should be used to describe AEs/ADEs', 'rather than colloquialisms (for example, \"influenza\\' rather than \"flu\\'), and', 'abbreviations should be avoided.', 'Adverse events/ADEs should be described using a specific clinical diagnosis, if this is', 'available, rather than a list of signs or symptoms (for example, \"congestive heart', \"failure' rather than 'dyspnea, rales, and cyanosis'). However, signs/symptoms that are\", 'not associated with an identified disease or syndrome, or for which an overall', 'diagnosis is not yet available, should be reported as individual AEs/ADEs.', 'Provisional diagnosis (e.g., \"suspected Myocardial Infarction\") is acceptable but', 'should be followed with a definite diagnosis (if available). Similarly, a fatal event', 'with an unknown cause should be recorded as \"Unknown\"', 'In cases of surgical or diagnostic procedures, the condition/illness leading to such a', 'procedure is considered as the AE/ADE rather than the procedure itself.', '9.9.1.', 'Investigator Assessments', '9.9.1.1.', 'Severity', 'Severity, which is a description of the intensity of manifestation of the AE/ADE, is distinct from', 'the regulatory definition of seriousness. The Investigator is required to grade the severity of each', 'AE/ADE according to the following guidelines.', 'Investigators must assess the severity/intensity of AEs/ADEs according to the following', 'qualitative toxicity scale:', 'Mild: Associated with no limitation of usual activities or only slight discomfort;', 'generally not requiring alteration or cessation of IMP administration; and/or not', 'needing therapeutic intervention.', 'Moderate: Associated with limitation of usual activities or significant discomfort;', 'generally requiring alteration or cessation of IMP administration; and/or requiring', 'therapeutic intervention.', 'Severe: Associated with inability of subject to carry out usual activities or very', 'marked discomfort; considered to be life-threatening; resulting in significant', 'disability or incapacity; and requiring therapeutic intervention.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '66']\n\n###\n\n", "completion": "END"}